DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

MSC for Treatment of cGVHD After Allo-HSCT

Phase 2

Conditions: Chronic Graft-versus-host Disease

Interventions: Biological: Mesenchymal stem cells
Drug: Glucocorticoids
Drug: cyclosporine

First Posted Date: 2020-12-31

Last Posted Date: 2020-12-31

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 152

Registration Number: NCT04692376

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Gut Microbiota and Serum Markers for Cognitive Impairment and Poor Prognosis After Ischemic Stroke

Conditions: Ischemic Stroke

First Posted Date: 2020-12-29

Last Posted Date: 2021-08-02

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 600

Registration Number: NCT04688138

Locations: 🇨🇳
Department of Neurology, NanFang Hospital, Southern Medical University, Guanzhou, Guangdong, China

Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia

Phase 2

Conditions: Acute Leukemia
Relapse
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Sorafenib

First Posted Date: 2020-12-19

Last Posted Date: 2021-11-08

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 346

Registration Number: NCT04674345

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

A Prospective Study of Application of Platelet Mapping in Chronic Liver Disease Complicated With ALI and/or AD in China

Completed

Conditions: Thrombelastography, Acute Liver Injury, Acute Decompensation, Platelet

First Posted Date: 2020-12-19

Last Posted Date: 2020-12-19

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 200

Registration Number: NCT04675125

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD

Not Applicable

Conditions: Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease

Interventions: Biological: Fecal Microbiota Transplant (FMT) Capsule

First Posted Date: 2020-11-10

Last Posted Date: 2020-11-10

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 10

Registration Number: NCT04622475

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

Phase 2

Completed

Conditions: B Cell Leukemia
B Cell Lymphoma

Interventions: Biological: CD19-CAR-T2 Cells

First Posted Date: 2020-10-28

Last Posted Date: 2024-08-20

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 77

Registration Number: NCT04605666

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia

Recruiting

Conditions: Validity and Safety

First Posted Date: 2020-10-19

Last Posted Date: 2022-04-12

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 200

Registration Number: NCT04591197

Locations: 🇨🇳
NanfangH, Guangzhou, Guangdong, China

A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China

Recruiting

Conditions: Metabolic Associated Fatty Liver Disease

First Posted Date: 2020-10-05

Last Posted Date: 2021-02-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 3000

Registration Number: NCT04573283

Locations: 🇨🇳
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Platelet Transfusion in Acute-on Chronic Liver Failure

Not Applicable

Conditions: Acute-On-Chronic Liver Failure

Interventions: Other: platelet transfusion

First Posted Date: 2020-09-25

Last Posted Date: 2020-09-25

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 80

Registration Number: NCT04564651

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China

and more 5 locations

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2020-09-10

Last Posted Date: 2020-09-10

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 87

Registration Number: NCT04544059

Locations: 🇨🇳
Nanfang hospital, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy